Luminal breast cancer commonly exhibits cyclin D1 and CDK4 amplification [20], while endocrine therapy-resistant tumors often exhibit deregulation of the CDK4/6 pathway [21]. The gene discussed is CDK4; the disease is breast tumor luminal A or B.